Sengenics Corporation Unveils i-Ome® Cancer: A Breakthrough in Cancer Precision Medicine
- Written by PR Newswire
![]() |
Revolutionizing Biomarker Discovery with a High-Throughput Immunoproteomic Platform
BOSTON, July 30, 2024 /PRNewswire/ -- Sengenics Corporation LLC is proud to announce the launch of i-Ome Cancer, a cutting-edge research tool designed to transform cancer biomarker discovery using just a drop of blood.
i-Ome Cancer marks a significant leap...
Read more: Sengenics Corporation Unveils i-Ome® Cancer: A Breakthrough in Cancer Precision Medicine















